How to buy Cerecor stock

Cerecor Inc is a biotechnology business based in the US. Cerecor shares (CERC) are listed on the NASDAQ and all prices are listed in US Dollars. Cerecor employs 30 staff and has a trailing 12-month revenue of around 0.00.

Cerecor share price

Use our graph to track the performance of CERC stocks over time.

Cerecor shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$1.97 - $4.50
50-day moving average	$2.91
200-day moving average	$2.84
Wall St. target price	$10.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.89

Buy Cerecor shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cerecor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cerecor Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cerecor financials

Revenue TTM	$6.7 million
Gross profit TTM	$-18,536,584
Return on assets TTM	-74.02%
Return on equity TTM	-282.65%
Profit margin	0%
Book value	$0.30
Market capitalisation	$251.2 million

TTM: trailing 12 months

Shorting Cerecor shares

There are currently 1.7 million Cerecor shares held short by investors – that's known as Cerecor's "short interest". This figure is 1.9% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting Cerecor shares can be evaluated.

Cerecor's "short interest ratio" (SIR)

Cerecor's "short interest ratio" (SIR) is the quantity of Cerecor shares currently shorted divided by the average quantity of Cerecor shares traded daily (recently around 442403.67454068). Cerecor's SIR currently stands at 3.81. In other words for every 100,000 Cerecor shares traded daily on the market, roughly 3810 shares are currently held short.

However Cerecor's short interest can also be evaluated against the total number of Cerecor shares, or, against the total number of tradable Cerecor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cerecor's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cerecor shares in existence, roughly 20 shares are currently held short) or 0.0285% of the tradable shares (for every 100,000 tradable Cerecor shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cerecor.

Find out more about how you can short Cerecor stock.

Cerecor share dividends

We're not expecting Cerecor to pay a dividend over the next 12 months.

Cerecor share price volatility

Over the last 12 months, Cerecor's shares have ranged in value from as little as $1.97 up to $4.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerecor's is 1.5797. This would suggest that Cerecor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cerecor overview

Cerecor Inc. , a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation.

Frequently asked questions

• What percentage of Cerecor is owned by insiders or institutions?

  Currently 0.783% of Cerecor shares are held by insiders and 66.211% by institutions.

• How many people work for Cerecor?

  Latest data suggests 30 work at Cerecor.

• When does the fiscal year end for Cerecor?

  Cerecor's fiscal year ends in December.

• Where is Cerecor based?

  Cerecor's address is: 540 Gaither Road, Rockville, MD, United States, 20850

• What is Cerecor's ISIN number?

  Cerecor's international securities identification number is: US15671L1098

• What is Cerecor's CUSIP number?

  Cerecor's Committee on Uniform Securities Identification Procedures number is: 15671L109